The company
Cabot Corporation
CBT · NYSE
CBT stood above a rising 150-day average in 16 of the last 52 weekly readings, and has been out of that trend for the last 8 weeks. It is 9.8% below that average now. Chemicals: 26% of its 85 stocks in an uptrend (−3 points in four weeks); Materials: 18% (−7 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 8
- Industry in uptrend
- 26% -4 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $39.3M
- Officials’ trades on record
- 4
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 16 of 52 weeks.
Chemicals: A minority of its stocks are in an uptrend and the share has been slipping. Materials: Few of its stocks are in an uptrend and the share has been slipping.
Money in and out
Open-market buys above the line and sales below, in dollars. Not yet read: institutions.
Congress and officials
4 disclosed lines: House 3, Senate 1, executive 0; 3 people.
| Who | Did | Amount | Traded |
|---|---|---|---|
| Lois Frankel House: U.S. House ClerkFL21 | sold | $1k–$15k | 4 Dec 2019filed 20 Dec 2019 |
| Lois Frankel House: U.S. House ClerkFL21 | sold | $1k–$15k | 3 Dec 2019filed 20 Dec 2019 |
| Thomas MacArthur House: U.S. House ClerkNJ03 | sold | $1k–$15k | 27 May 2015filed 7 Jun 2015 |
| Susan M. Collins Senate: U.S. Senate eFDSenator | soldspouse | $1k–$15k | 7 May 2014filed 16 May 2014 |
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Sean D. KeohanePresident and CEO | sold | 134,895at $85.00 | 28 Aug 2026filed 31 Aug 2026 |
| Sean D. KeohanePresident and CEO | sold | 2,779at $85.50 | 24 Aug 2026filed 26 Aug 2026 |
| Sean D. KeohanePresident and CEO | sold | 91,923at $86.41 | 7 Aug 2026filed 11 Aug 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Still reading this part; it fills in a moment.
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.